What is the price of zomedica stock now?
This is big news for ZOM stock, which has a market capitalization of $367.6 million and a big milestone to celebrate. The reason is that in 2020, reported revenue was non-existent. Source:...
What does Zom stand for?
Apr 08, 2022 · Real-time trade and investing ideas on Zomedica Pharmaceuticals Corp ZOM from the largest community of traders and investors. Rooms Shows Rankings Earnings Newsletters Shop. Cancel. Log In. Sign Up. DOW 0.00%. S&P 500 0.00%. NASDAQ 0.00%. Trending now. Zomedica Pharmaceuticals Corp 0.31 0.01 (2.31%) Watch.
Where can I buy shares of Zom?
Mar 25, 2022 · ZOM | Complete Zomedica Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Is Zom stock still a buy after 14% gain in August?
Mar 31, 2022 · Zomedica Corp. (NYSEAMERICAN:ZOM) issued its quarterly earnings results on Thursday, November, 12th. The company reported ($0.01) earnings per share (EPS) for the quarter. Zomedica had a negative net margin of 444.70% and a negative trailing twelve-month return on equity of 6.71%. View Zomedica's earnings history.
Is ZOM a good stock to buy?
ZOM stock could provide some good gains in the long term if its veterinary diagnostic and therapeutic technologies can gain sufficient market traction. However, the stock remains a speculative investment that owed its previous tops to the Reddit meme that lifted other stocks like GameStop and AMC.Feb 4, 2022
Is ZOM stock a buy or sell?
The Zomedica Pharmaceuticals Corp stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
Who owns the most ZOM stock?
The Vanguard Group, Inc.Top 10 Owners of Zomedica CorpStockholderStakeShares ownedThe Vanguard Group, Inc.4.14%40,612,378SSgA Funds Management, Inc.2.93%28,730,202BlackRock Fund Advisors1.19%11,691,103Cambridge Investment Research Adv...1.14%11,142,6606 more rows
Will ZOM be delisted?
(NYSE American: ZOM) (TSX-V: ZOM) (“Zomedica” or the “Company”) a veterinary diagnostic and pharmaceutical company, today announced that it has received approval of its application to delist its common shares from the TSX Venture Exchange (“TSXV”) effective at the close of business on February 10, 2020.Jan 30, 2020
Will ZOM recover?
ZOM stock will likely struggle to recover in price over the next few months. It's going to be awhile before this early stage company will again have the chance to prove itself to investors. Having said that, investors with a high appetite for risk, and a willingness to go against the grain, may want to buy today.Oct 7, 2021
Is ZOM overvalued?
Zomedica Pharmaceuticals seems to be overvalued based on Macroaxis valuation methodology.
Did BlackRock buy Zom stock?
- 13F, 13D, 13G Filings - Fintel.io....BlackRock Inc. reports 29.83% decrease in ownership of ZOM / Zomedica Pharmaceuticals Corp.SecurityZOM / Zomedica Pharmaceuticals Corp.Latest Disclosed Value$ 3,896,0002 more rows
Which institutions are buying Zom?
Zomedica (NYSEAMERICAN:ZOM) Institutional Buying and Selling Pinnacle Wealth Management Group Inc. BlackRock Inc. Goldman Sachs Group Inc. Victory Capital Management Inc.
Is Vanguard invested in Zomedica?
Vanguard Group Inc reports 0.44% increase in ownership of ZOM / Zomedica Pharmaceuticals Corp. 2022-02-14 - Vanguard Group Inc has filed a 13F-HR form disclosing ownership of 41,635,682 shares of Zomedica Pharmaceuticals Corp. (US:ZOM) with total holdings valued at $12,762,000 USD as of 2021-12-31.
Why is ZOM stock going down?
CEO Robert Cohen said the move was precipitated by "changes at our current distributor that we believe have impacted its ability to market our products effectively." Those words likely startled investors, many of whom decided to sell their shares. Zomedica's stock price dropped sharply on Thursday.Apr 15, 2021
How has Zomedica's stock been impacted by COVID-19 (Coronavirus)?
Zomedica's stock was trading at $0.2078 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organ...
When is Zomedica's next earnings date?
Zomedica is scheduled to release its next quarterly earnings announcement on Tuesday, May 10th 2022. View our earnings forecast for Zomedica .
How were Zomedica's earnings last quarter?
Zomedica Corp. (NYSEAMERICAN:ZOM) issued its quarterly earnings results on Thursday, November, 12th. The company reported ($0.01) earnings per shar...
What guidance has Zomedica issued on next quarter's earnings?
Zomedica issued an update on its FY 2021 earnings guidance on Monday, March, 14th. The company provided earnings per share (EPS) guidance of for th...
Who are Zomedica's key executives?
Zomedica's management team includes the following people: Mr. Robert Cohen , CEO & Director (Age 63, Pay $412.79k) Ms. Ann Marie Cotter CPA , C...
Who are some of Zomedica's key competitors?
Some companies that are related to Zomedica include Protagonist Therapeutics (PTGX) , Keros Therapeutics (KROS) , Myovant Sciences (MYOV) , Axs...
What is Zomedica's stock symbol?
Zomedica trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ZOM."
Who are Zomedica's major shareholders?
Zomedica's stock is owned by a variety of retail and institutional investors. Top institutional investors include State Street Corp (2.93%), BlackR...
Which institutional investors are selling Zomedica stock?
ZOM stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Commonwealt...
About Zomedica
Zomedica (NYSEAMERICAN:ZOM) Frequently Asked Questions
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs.
Signals & Forecast
Zomedica's stock was trading at $0.2078 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ZOM stock has increased by 63.8% and is now trading at $0.3403. View which stocks have been most impacted by COVID-19.
Support, Risk & Stop-loss
The Zomedica Pharmaceuticals Corp stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.
Is Zomedica Pharmaceuticals Corp stock A Buy?
Zomedica Pharmaceuticals Corp finds support from accumulated volume at $0.36 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are very positive buying more shares than they are selling in Zomedica Pharmaceuticals Corp
Zomedica Pharmaceuticals Corp holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
Golden Star Signal
In the last 100 trades there were 77.16 million shares bought and 11.3 million shares sold. The last trade was done 97 days ago by Powers Johnny D who bough 250 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
What is Zomedica?
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
ZOM Stock History
Zomedica Corp. is a veterinary pharmaceutical company.
Zomedica: Strategy & Potential Catalysts
Zomedica shares came to the US market in late 2017, initially priced near $1 per share on the NYSE American exchange (AMEX). The NYSE American exchange is specifically designed for small-cap companies, growing firms that cannot yet meet the stricter requirements imposed by the larger and more prominent New York Stock Exchange.
ZOM Stock Analysis
Much of the fundamental news around Zomedica since its existence as a US public company has been negative. The company has burned through cash, had numerous execution failures, installed new management teams and has faced a continuous prospect of delisting from the AMEX exchange.
